214 related articles for article (PubMed ID: 37549066)
1. Genomic alterations affecting tumor-infiltrating lymphocytes and PD-L1 expression patterns in triple-negative breast cancer.
Wang H; Ding XH; Liu CL; Xiao Y; Shui RH; Li YP; Chen C; Yang WT; Liu S; Chen CS; Shao ZM; Jiang YZ
J Natl Cancer Inst; 2023 Dec; 115(12):1586-1596. PubMed ID: 37549066
[TBL] [Abstract][Full Text] [Related]
2. Assessing the relationship between tumor-infiltrating lymphocytes and PD-L1 expression in triple negative breast cancer: Identifying optimal TILs cut-off value for pathologic reporting.
Suwannaphoom K; Soontornsit S; Wiwatwarayos K; Seneetuntigul P; Julimasart P
Ann Diagn Pathol; 2024 Jun; 70():152294. PubMed ID: 38513466
[TBL] [Abstract][Full Text] [Related]
3. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M
Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168
[TBL] [Abstract][Full Text] [Related]
4. Molecular Characteristics of Lymphocyte-predominant Triple-negative Breast Cancer.
Sasaki R; Horimoto Y; Yanai Y; Kurisaki-Arakawa A; Arakawa A; Nakai K; Saito M; Saito T
Anticancer Res; 2021 Apr; 41(4):2133-2140. PubMed ID: 33813424
[TBL] [Abstract][Full Text] [Related]
5. PD-L1 expression in tumor infiltrated lymphocytes predicts survival in triple-negative breast cancer.
Wang X; Liu Y
Pathol Res Pract; 2020 Mar; 216(3):152802. PubMed ID: 32005408
[TBL] [Abstract][Full Text] [Related]
6. Expression of PD-L1 Attenuates the Positive Impacts of High-level Tumor-infiltrating Lymphocytes on Prognosis of Triple-negative Breast Cancer.
Zhu X; Zhang Q; Wang D; Liu C; Han B; Yang JM
Cancer Biol Ther; 2019; 20(8):1105-1112. PubMed ID: 30929569
[No Abstract] [Full Text] [Related]
7. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy.
Dieci MV; Tsvetkova V; Griguolo G; Miglietta F; Tasca G; Giorgi CA; Cumerlato E; Massa D; Lo Mele M; Orvieto E; Guarneri V; Conte P
Eur J Cancer; 2020 Sep; 136():7-15. PubMed ID: 32622323
[TBL] [Abstract][Full Text] [Related]
8. Integrative prognostic analysis of tumor-infiltrating lymphocytes, CD8, CD20, programmed cell death-ligand 1, and tertiary lymphoid structures in patients with early-stage triple-negative breast cancer who did not receive adjuvant chemotherapy.
Yazaki S; Shimoi T; Yoshida M; Sumiyoshi-Okuma H; Arakaki M; Saito A; Kita S; Yamamoto K; Kojima Y; Nishikawa T; Tanioka M; Sudo K; Noguchi E; Murata T; Shiino S; Takayama S; Suto A; Ohe Y; Fujiwara Y; Yonemori K
Breast Cancer Res Treat; 2023 Jan; 197(2):287-297. PubMed ID: 36385236
[TBL] [Abstract][Full Text] [Related]
9. The predictive and prognostic value of Foxp3+/CD25+ regulatory T cells and PD-L1 expression in triple negative breast cancer.
Zhang L; Wang XI; Ding J; Sun Q; Zhang S
Ann Diagn Pathol; 2019 Jun; 40():143-151. PubMed ID: 31096176
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Role and Clinical Association of Tumor-Infiltrating Lymphocyte, Programmed Death Ligand-1 Expression with Neutrophil-Lymphocyte Ratio in Locally Advanced Triple-Negative Breast Cancer.
Lee J; Kim DM; Lee A
Cancer Res Treat; 2019 Apr; 51(2):649-663. PubMed ID: 30064200
[TBL] [Abstract][Full Text] [Related]
11. Markers associated with genomic instability, immunogenicity and immune therapy responsiveness in Metaplastic carcinoma of the breast: Expression of γH2AX, pRPA2, P53, PD-L1 and tumor infiltrating lymphocytes in 76 cases.
Voutilainen S; Heikkilä P; Bartkova J; Nevanlinna H; Blomqvist C; Bartek J; Mattson J
BMC Cancer; 2022 Dec; 22(1):1298. PubMed ID: 36503417
[TBL] [Abstract][Full Text] [Related]
12. The combined presence of CD20 + B cells and PD-L1 + tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome.
Arias-Pulido H; Cimino-Mathews A; Chaher N; Qualls C; Joste N; Colpaert C; Marotti JD; Foisey M; Prossnitz ER; Emens LA; Fiering S
Breast Cancer Res Treat; 2018 Sep; 171(2):273-282. PubMed ID: 29858752
[TBL] [Abstract][Full Text] [Related]
13. Multispectral quantitative immunohistochemical analysis of tumor-infiltrating lymphocytes in relation to programmed death-ligand 1 expression in triple-negative breast cancer.
Sugie T; Sato E; Miyashita M; Yamaguchi R; Sakatani T; Kozuka Y; Moritani S; Suzuki E; Kakimi K; Mikami Y; Moriya T
Breast Cancer; 2020 Jul; 27(4):519-526. PubMed ID: 32447649
[TBL] [Abstract][Full Text] [Related]
14. Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer.
Li M; Li A; Zhou S; Xu Y; Xiao Y; Bi R; Yang W
BMC Cancer; 2018 Jan; 18(1):4. PubMed ID: 29291717
[TBL] [Abstract][Full Text] [Related]
15. Characterization of immune checkpoints expression and lymphocyte densities of iranian breast cancer patients; the co-expression status and clinicopathological associates.
Pournabee M; Keshavarz-Fathi M; Esmaeili P; Mahdavi Sharif P; Nili F; Jahanbin B
BMC Cancer; 2023 Jun; 23(1):495. PubMed ID: 37264298
[TBL] [Abstract][Full Text] [Related]
16. Can evaluation of mismatch repair defect and TILs increase the number of triple-negative breast cancer patients eligible for immunotherapy?
Özcan D; Lade-Keller J; Tramm T
Pathol Res Pract; 2021 Oct; 226():153606. PubMed ID: 34530255
[TBL] [Abstract][Full Text] [Related]
17. The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice.
Gonzalez-Ericsson PI; Stovgaard ES; Sua LF; Reisenbichler E; Kos Z; Carter JM; Michiels S; Le Quesne J; Nielsen TO; Laenkholm AV; Fox SB; Adam J; Bartlett JM; Rimm DL; Quinn C; Peeters D; Dieci MV; Vincent-Salomon A; Cree I; Hida AI; Balko JM; Haynes HR; Frahm I; Acosta-Haab G; Balancin M; Bellolio E; Yang W; Kirtani P; Sugie T; Ehinger A; Castaneda CA; Kok M; McArthur H; Siziopikou K; Badve S; Fineberg S; Gown A; Viale G; Schnitt SJ; Pruneri G; Penault-Llorca F; Hewitt S; Thompson EA; Allison KH; Symmans WF; Bellizzi AM; Brogi E; Moore DA; Larsimont D; Dillon DA; Lazar A; Lien H; Goetz MP; Broeckx G; El Bairi K; Harbeck N; Cimino-Mathews A; Sotiriou C; Adams S; Liu SW; Loibl S; Chen IC; Lakhani SR; Juco JW; Denkert C; Blackley EF; Demaria S; Leon-Ferre R; Gluz O; Zardavas D; Emancipator K; Ely S; Loi S; Salgado R; Sanders M;
J Pathol; 2020 Apr; 250(5):667-684. PubMed ID: 32129476
[TBL] [Abstract][Full Text] [Related]
18. The association of genomic lesions and PD-1/PD-L1 expression in resected triple-negative breast cancers.
Barrett MT; Lenkiewicz E; Malasi S; Basu A; Yearley JH; Annamalai L; McCullough AE; Kosiorek HE; Narang P; Wilson Sayres MA; Chen M; Anderson KS; Pockaj BA
Breast Cancer Res; 2018 Jul; 20(1):71. PubMed ID: 29996881
[TBL] [Abstract][Full Text] [Related]
19. p53 Missense Mutation is Associated with Immune Cell PD-L1 Expression in Triple-Negative Breast Cancer.
Xing AY; Liu L; Liang K; Wang B
Cancer Invest; 2022 Nov; 40(10):879-888. PubMed ID: 35980253
[TBL] [Abstract][Full Text] [Related]
20. The combination of PD-L1 expression and decreased tumor-infiltrating lymphocytes is associated with a poor prognosis in triple-negative breast cancer.
Mori H; Kubo M; Yamaguchi R; Nishimura R; Osako T; Arima N; Okumura Y; Okido M; Yamada M; Kai M; Kishimoto J; Oda Y; Nakamura M
Oncotarget; 2017 Feb; 8(9):15584-15592. PubMed ID: 28107186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
